更新于：2024-11-01

Spectrum Health Hospitals, Inc.

子公司|

Michigan, United States

子公司|

Michigan, United States

更新于：2024-11-01

概览

关联

项与 Spectrum Health Hospitals, Inc. 相关的临床试验

NCT06422273 / Enrolling by invitation临床3期IIT

Prophylactic Use of Tranexamic Acid Versus Saline to Prevent Bleeding During Transbronchial Biopsy in Lung Transplant Recipients- A Randomized Double-Blind Trial (Protest Trial)

To determine if endobronchial (topical) tranexamic acid used prophylactically prior to performing transbronchial biopsies in lung transplant recipients reduces bleeding risk.

开始日期2024-04-16

申办/合作机构

Spectrum Health Hospitals, Inc.

NCT05986890 / RecruitingN/AIIT

Roux-en-Y Gastric Bypass Versus Loop Gastrojejunostomy for Malignant Gastric Outlet Obstruction

This study is intended to investigate whether roux-en-y bypass surgery is superior to conventional loop gastrojejunostomy for Malignant gastric outlet obstruction in terms of tolerance to solid food intake. We hypothesize that roux-en-y bypass will be associated with improved solid food intake in the first 30 days after surgery.

开始日期2023-08-17

申办/合作机构

Spectrum Health Hospitals, Inc.

NCT05386316 / Enrolling by invitationN/AIIT

Meeting Women Where They Are: The Maternal Health Multilevel Intervention for Racial Equity (MIRACLE) Project

This community-partnered study will scale a community, provider, and system-level implementation intervention to reduce African American maternal morbidity and mortality disparities in two Michigan counties (Genesee and Kent). This project will test the intervention using data from Medicaid insured women who deliver in Michigan from 2016-2019 and 2022-2025 (approximately 540,000 births, including 162,000 births to African American women).

开始日期2022-01-01

申办/合作机构

Michigan State University

[+1]

100 项与 Spectrum Health Hospitals, Inc. 相关的临床结果

登录后查看更多信息

0 项与 Spectrum Health Hospitals, Inc. 相关的专利（医药）

登录后查看更多信息

项与 Spectrum Health Hospitals, Inc. 相关的文献（医药）

2022-03-01·Chest1区 · 医学

Bronchial Thermoplasty in Patients With Severe Asthma at 5 Years

1区 · 医学

Article

作者: Wahidi, Momen M ; Kline, Joel N ; LaCamera, Peter ; Shifren, Adrian ; Trevor, Jennifer ; Castro, Mario ; Simoff, Michael ; Kahlstrom, Nick ; Dransfield, Mark ; Grubb, G Mark ; Fitzgerald, J Mark ; McMullen, Edmund A ; Hey, Jamie ; Chupp, Geoffrey ; McClelland, Marc ; McEvoy, Charlene ; Hogarth, D Kyle ; Ferguson, J Scott ; Tejedor, Richard ; Haas, Andrew ; Khatri, Sumita B ; Laviolette, Michel ; Enfield, Kyle ; Lamb, Carla R ; Bansal, Sundeep ; Toth, Jennifer ; Olson, Jennifer L ; Majid, Adnan ; Silvestri, Gerard A

BACKGROUNDBronchial thermoplasty is a device-based treatment for subjects ≥ 18 years of age with severe asthma poorly controlled with inhaled corticosteroids and long-acting beta-agonists. The Post-FDA Approval Clinical Trial Evaluating Bronchial Thermoplasty in Severe Persistent Asthma (PAS2) study collected data on patients with severe asthma undergoing this procedure.RESEARCH QUESTIONWhat are the 5-year efficacy and safety results in patients with severe asthma who have undergone bronchial thermoplasty?STUDY DESIGN AND METHODSThis was a prospective, open-label, observational, multicenter study conducted in the United States and Canada. Subjects 18 to 65 years of age who were taking inhaled corticosteroids ≥ 1,000 μg/d (beclomethasone or equivalent) and long-acting beta-agonists ≥ 80 μg/d (salmeterol or equivalent) were included. Severe exacerbations, hospitalization, ED visits, and medication usage were evaluated for the 12 months prior to and at years 1 through 5 posttreatment. Spirometry was evaluated at baseline and at years 1 through 5 posttreatment.RESULTSA total of 284 subjects were enrolled at 27 centers; 227 subjects (80%) completed 5 years of follow-up. By year 5 posttreatment, the proportion of subjects with severe exacerbations, ED visits, and hospitalizations was 42.7%, 7.9%, and 4.8%, respectively, compared with 77.8%, 29.4%, and 16.1% in the 12 months prior to treatment. The proportion of subjects on maintenance oral corticosteroids decreased from 19.4% at baseline to 9.7% at 5 years. Analyses of subgroups based on baseline clinical and biomarker characteristics revealed a statistically significant clinical improvement among all subgroups.INTERPRETATIONFive years after treatment, subjects experienced decreases in severe exacerbations, hospitalizations, ED visits, and corticosteroid exposure. All subgroups demonstrated clinically significant improvement, suggesting that bronchial thermoplasty improves asthma control in different asthma phenotypes.CLINICAL TRIAL REGISTRATIONClinicalTrials.gov; No.: NCT01350336; URL: www.CLINICALTRIALSgov.

2021-12-01·Clinics in Laboratory Medicine4区 · 医学

Granulocyte Transfusion

4区 · 医学

Review

作者: Cohen, Tobias ; Pham, Huy P ; Simmons, Sierra C ; Staley, Elizabeth M

Neutrophils are an integral component of the innate immune system and key regulators of cell-mediated defense against bacterial and fungal pathogens. The potential of granulocyte transfusions has been investigated to temporarily replenish innate immune function to prevent and/or treat infections in patients with severe neutropenia or neutrophil dysfunction. However, evidence has been largely theoretical, experimental, and/or inconclusive. Clinical efficacy has yet to be confirmed by large-scale randomized controlled clinical trials. Performing such trials has been hampered by low granulocyte collection yield and poor patient accrual. We provide a practical summary of the current literature surrounding the practice of granulocyte transfusion.

2019-05-01·Journal of Vascular and Interventional Radiology3区 · 医学

Preservation of Cardiopulmonary Function in Patients Treated with Ultrasound-Accelerated Thrombolysis in the Setting of Submassive Pulmonary Embolism

3区 · 医学

Article

作者: Eberhart, Lenora ; Berjaoui, Wael K ; Langholz, David E ; Knox, Michael F

PURPOSETo evaluate the clinical effectiveness of ultrasound-assisted thrombolysis (USAT) in resolution of right ventricular dysfunction (RVD), preservation of cardiopulmonary function, and quality of life (QoL) in patients with acute submassive pulmonary embolism (PE).MATERIALS AND METHODSA single-center prospective study of patients presenting with acute PE and signs of RVD, as determined by right ventricle-to-left ventricle diameter ratio (RV:LV) > 0.9 on computed tomographic angiography of the thorax, was performed. Patients underwent USAT with recombinant tissue plasminogen activator. Primary endpoints measured were RV:LV by echocardiogram at baseline presentation and at 72 hours and 90 days after treatment. Secondary endpoints were QoL scores assessed by SF-36 Health Surveys at baseline and at 90 days, cardiopulmonary exercise test (CPET) parameters at 90 days, and procedural outcomes, including response of pulmonary artery pressure (PAP) and procedural complications.RESULTSTwenty-five patients were treated between June 17, 2013, and September 15, 2014, with mean reduction of RV:LV by echocardiogram from 1.38 ± 0.28 at presentation to 0.92 ± 0.14 (P < .0001) at 72 hours and 0.84 ± 0.25 (P < .0001) at 90 days. SF-36 Health Survey scores demonstrated no long-term self-perceived adverse physical or mental effects as a result of PE. CPET parameters, including VO2_max, weight-adjusted VO2, VE/VCO2, and VD/VT demonstrated no pulmonary vascular impairment at 90 days. PAP significantly improved after USAT, with mean initial systolic pressure of 50.46 ± 13.98 mmHg reduced to 39.64 ± 8.66 mmHg (P = .0001). There were no deaths, recurrent venous thromboembolism, hemodynamic decompensation, or hemorrhage.CONCLUSIONSUSAT resulted in significant reduction of RV:LV at 72 hours, which was preserved at 90 days. QoL and objective measures of cardiopulmonary function are preserved at 90 days in this population. Further studies with long-term follow-up are needed to determine the potential value of USAT for the prevention of post-PE syndrome in patients with submassive PE.

100 项与 Spectrum Health Hospitals, Inc. 相关的药物交易

登录后查看更多信息

100 项与 Spectrum Health Hospitals, Inc. 相关的转化医学

登录后查看更多信息